

BRISBANE CANCER CONFERENCE

28 – 29 November 2024

Brisbane Convention
and Exhibition Centre

20
24



PROGRAM



Conference Sponsors

Platinum Sponsor



Gold Sponsors



Silver Sponsor



Bronze Sponsors



Other Sponsors



Welcome

Dear Colleagues,

Welcome to the 11th Annual Brisbane Cancer Conference. With the establishment of Health Translation Queensland as an NHMRC Research and Translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical developments in the diagnosis and treatment of malignant disease.

On Thursday 28th November, the meeting will start 8.00am with Breast, Lung and Prostate Cancer, Survivorship, and Immunotherapy symposia running from 8 – 11pm in the morning. The symposia will be followed by satellite symposia and plenary lectures. Subsequently there will be workshops from 4:30 – 6:30pm.

The symposium Gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues and patient advocates and consumers from other institutions, the city and Queensland.


The all-day session on Friday 29th November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon. A key session will be lectures by Queensland oncology researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology, and treatment of malignant disease.

Over 1,000 delegates registered for the event last year demonstrating the value of a truly multi- disciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation, our many sponsors, the time and effort of the chairs who put the workshops together as well as Therese and the QUT Cancer and Ageing Research Program (CARP) team.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,



Professor Ken O'Byrne
Consultant Medical Oncologist

Princess Alexandra Hospital,
Translational Research Institute and
Queensland University of Technology

Conference Program

THURSDAY 28 NOVEMBER, 2024

DAY
1

7am Registration Opens

Coffee cart (supported by Translational Research Institute, Australia)

Symposia (8.00 – 11.45)

Morning tea supported by AstraZeneca

Survivorship (supported by MSD)

Plaza Level, P6

Chairs: Laurelie Wishart, Harry Gasper

- 08.00 Welcome and update from Queensland Collaborative for Cancer Survivorship – Kim Alexander
- 08.15 Co-designing post-treatment survivorship care for Queenslanders: A new program to improve social connection and health outcomes in women impacted by cancer – Christina Lowe, Xanthia Bourdaniotis
- 08.30 Survivorship Care in Paediatrics: Development of a model of care for end of treatment – the RECOVER Project – Shelley Rumble
- 08.45 Survivorship Care in Adults: My First 70 days as a Survivorship Nurse Navigator – Leilani Way
- 09.00 Survivorship in a Shared Care setting: Shared Care for Early Breast Cancer – Toowoomba Hospital experience – Marion Strong
- 09.15 Survivorship Care Regional and Rural perspective: Implementing a shared care model to enable regional/rural patients with head and neck cancer to access local speech pathology care – Corey Patterson
- 09.30 Survivorship Care in First Nations Queenslanders: Blood cancers – Jodie Jetann, Dr Shafkat Jahan, Gail Garvey
- 09.45 Exercise in Survivorship: An individualised exercise intervention improves health outcomes for people with Multiple myeloma: The MyeEx randomised wait-list controlled trial – Brent Cunningham

10.00 Morning tea

- 10.20 Panel discussion and workshop: Survivorship care plans: What's their value and can/do we operationalise them?
Panel – Harry Gasper, Sharon Donaldson, Marion Strong, Carla Thamm, Corey Patterson, Makala Castelli
- 11.20 Session concluding remarks

Breast Cancer (supported by AstraZeneca)

Plaza Level, P7 & P8

Chairs: Peter Simpson, Rik Thompson, Jasotha Sanmugarajah

- 08.00 Welcome and introduction
- 08.05 Denosumab as primary prevention of Breast cancer in females with a germline BRCA1 mutation – Christian Singer
- 08.20 Identification of breast cancer risk genes which modulate responses to immune mediated destruction – Jonathan Beesley
- 08.40 The transformative potential of mRNA cancer vaccines – Seth Cheetham
- 09.00 Novel immunotherapeutic targets to treat primary and metastatic breast cancer – Roberta Mazzeri
- 09.20 Addition of the therapeutic MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial – Christian Singer
- 10.00 **Morning tea**
- 10.30 Clinical trials in immuno-oncology – Nicole Pringle
- 10.45 Antibody Drug Conjugates in Breast Cancer – Rebecca Moor
- 11.00 The Enhancing Women's Recovery after Cancer Treatment Program (RECENTRE): A values-based implementation and evaluation – Janine Porter-Steele & Sarah Balaam
- 11.15 It's About More Than Sex: Examining Sexual Wellbeing in Younger Women After Breast Cancer – Mackenzie Petie
- 11.30 Q&A and concluding remarks

Prostate Cancer (supported by Janssen)

Plaza Level, P9

Chairs: Chun Gan, Michael Huo, Colleen Nelson

Session 1 – Advancements in Clinical Care

- 08.00 Radiology: prostate MRI tips, pitfalls and utility post prostatectomy – Sonja Gustafson
- 08.17 Medical oncology: Future direction in systemic therapy in mCRPC – Aaron Hansen
- 08.34 Radiation oncology: Salvage SBRT – David Pryor
- 08.51 Exercise physiology: ERADICATE trial – Robert Newton
- 09.08 Urology: Retzius sparing prostatectomy – Ross Fowler
- 09.25 Physiotherapy: Pelvic floor muscle rehabilitation for incontinence – David Cowley
- 09.42 Discussion/QA

10.00 Morning tea

Session 2 – Translational Research

- 10.30 Preclinical development of new targeted therapeutic strategy for advanced prostate cancer – Lisa Philp
- 10.50 A novel targeted therapy for treatment-emergent anaplastic forms of CRPC – Brett Hollier
- 11.10 Identification of a Novel Micro-Peptide (miPEP) and Its Role in Prostate Cancer Stemness – Achala Vitharanage
- 11.30 Q&A and concluding remarks

Conference Program

THURSDAY 28 NOVEMBER, 2024

DAY
1

Advances in immuno-oncology (supported by BMS)

Plaza Level, P10 & P11

Chairs: Antiopi Varelias, Kenneth O'Byrne

- 08.00 Recent advances in I-O therapy – Rahul Ladwa
- 08.20 Update on biomarkers – Kenneth O'Byrne
- 08.40 Spatial atlas of I-O mediated dynamics of the tumour draining lymph node – Monika Prelowska
- 09.00 Combinations I-O therapy with Antibody-Drug Conjugates – Adnan Nagrial
- 09.20 Cancer Vaccines: Principles and Practice – Liam O'Brien
- 09.40 CD8 T-cell anti-tumour immunity to resolve I-O therapy resistance – Jiajie (Jet) Hou (video)

10.00 Morning tea

- 10.20 BITES – Laura Tam
- 10.40 CAR-T cells solid tumours - Rajiv Khanna
- 11.00 CAR-T cells Haematological Malignancies – Andrea Henden
- 11.20 Cell based therapy toxicity management, CRS and ICANS, from the nurse perspective – Michelle Beutel & Nicola Roborgh
- 11.40 Q&A and concluding remarks

Lung Cancer Symposium (supported by Lung Foundation Australia)

Sky Level, S1

Chairs: Henry Marshall, Michelle Murphy

Lung cancer screening: Is Queensland ready yet?

- 08.00 Role out of the Australian Lung Cancer program – Henry Marshall
- 08.20 Pulmonary nodule MDT workflows – Gerry Olive
- 08.40 Imaging assessments for pulmonary nodules – Catherine Jones (video)
- 09.00 When and how to biopsy pulmonary nodules – David Fielding
- 09.20 Engaging the First Nations Population – Zulfiqar Otti
- 09.40 Panel discussion: Screening in Queensland

10.00 Morning tea

- 10.20 Clinical trials for Stage I lung cancer – Adnan Nagrial
- 10.35 Role of radiotherapy in Stage I disease – Catherine Bettington
- 10.50 The surgeon's perspective – Paul Peters
- 11.05 Diagnostic biomarkers – Chaminde Punyadeera
- 11.20 Q&A and concluding remarks

11.45 Break

Industry Symposia (12.00 – 13.30)

Plaza Level, P6 – P8

Satellite Session 1 (12.00 – 12.45) sponsored by BMS

Panel: Linda Denehy, Bryan Chan, Niara Oliveira

Evolving Multidisciplinary Teams (MDTs) and the Impact on Early-Stage Oncology Care: Best Practices in Accelerating Standards of Care

- Presentation – Linda Denehy
- Panel discussion

Satellite Session 2 (12.45 – 13.30) supported by MSD

Chair: Sandro Porceddu

How are we doing with advanced H&N cancer?

- Presentation – Margie McGrath
- Panel discussion: Howard Liu, Emma Mitchell

Lunch (13.30 – 14.00) supported by BMS & MSD

Plenary Lectures (14.00 – 16.00)

Plaza Auditorium

Chairs: Damian Topp, Aniko Cooper

- 14.00 Australian Comprehensive Cancer Network for achieving Health Equity – Sabe Sabesan
- 14.17 Recent advances in breast cancer genomics – Pete Simpson
- 14.34 Updates on Sarcoma – Vladimir Andelkovic
- 14.51 Evolution in Care of Early Bladder Cancer – Jeff Goh
- 15.08 Brisbane theranostics: the next generation – David Pattison
- 15.25 Empowering Survivorship: opportunities for personalised care in the digital age – Makala Castelli
- 15.42 Health Consumer in the research cycle, a real-life perspective – Alison Bolton

Refreshments (16.00 – 16.30)

Conference Program

THURSDAY 28 NOVEMBER, 2024

DAY
1

Parallel Workshops (16.30 – 18.00)

Bone and soft tissue tumours

Plaza Level, P6

Chairs: Vladimir Andelkovic, Philip Rowell

- 16.30 Spatial profiling of tumour microenvironment uncovers a potential novel combinatorial approach in paediatric rhabdomyosarcoma – Cui (Maxine) Tu
- 16.45 Establishment, characterisation and phenotypic profiling of primary osteosarcoma in 2D & 3D matrix environments – Bhatia Sugandha
- 17.00 Clinical Utility of Next Generation Sequencing in AYA Sarcoma Patients in an Australian Sarcoma Specialist Centre – Karan Gupta
- 17.15 Tumour Genomic Profiling and Treatment Response Assessment in Sarcoma Patient-Derived Organoid (PDO) Models – Laura Croft
- 17.30 Genomics and pathology perspective in sarcoma samples – James Bennett
- 17.45 Queensland Sarcoma Stakeholder Meeting – Vladimir Andelkovic (17.45 – 18.30)

Genomics

Plaza Level, P7

Chairs: Quan Nguyen, Mark Adams, Nic Waddell

- 16.30 Mapping the neoadjuvant immunotherapy-associated remodeling of the non-small cell lung cancer tumour microenvironment – Bill Dougall
- 16.47 ctDNA monitoring assays in cancer – Paul leo
- 17.04 Investigating structural variants and methylation in lung cancer through long-read sequencing – Lingchen Liu
- 17.21 A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer – Sri Srinivasan
- 17.38 Unveiling Cancer's Sweet Secrets: Spatially Resolved Mass Spectrometry Imaging of Glycans in the Tumour Microenvironments – Arun Everest
- 17.55 Concluding remarks

Theranostics

Plaza Level, P8

Chairs: David Pattison, Kristofer Thurecht

- 16.30 Clinical trials landscape in theranostics in Australia – Roslyn Francis
- 16.50 Evaluating mRNA delivery using nuclear medicine – James Humphries
- 17.00 Developing a new chelator for the rapid and stable complexation of the α -generators bismuth-212 and lead-212 – Melyssa Grieve
- 17.10 Evaluation of a new cancer theranostic for ovarian and bladder cancer – John Hooper
- 17.20 Theranostics in 2025: an overview – Nattakorn Dhantravan
- 17.30 Theranostics update from PAH – Stanley Ngai
- 17.40 Panel Discussion – The Future of Theranostics in Queensland
- 17.50 Final comments and questions

GU malignancies

Plaza Level, P9

Chairs: Niara Oliveira, Jeff Goh, Elizabeth Williams

- 16.30 3D organoids for identifying treatment options and drug development – Elizabeth Williams
- 16.45 Caring for patients with a neobladder: nursing and allied health perspectives – Michelle Roberts & David Cowley
- 17.05 Antibody-drug conjugates and new mechanisms of action in bladder cancer – Niara Oliveira
- 17.20 Role of Belzutifan for Von Hippel-Lindau renal cell carcinoma – Simon Wood
- 17.40 Adjuvant immunotherapy in Renal Cell Cancer – Jeff Goh

Cancer Alliance QOOL Data

Plaza Level, P10

Chair: Euan Walpole

Monitoring the impact of cancer on Queenslanders: A comprehensive review of Lung, Pancreas and Merkel Cell Carcinoma

- 16.30 Introduction
- 16.40 Do patient characteristics influence the first-line chemotherapy regimen for adenocarcinoma of the pancreas? – Euan Walpole
- 17.00 Variation in Merkel Cell Carcinoma Outcomes: A Queensland Perspective on a Rare and Aggressive Skin Cancer – Wen Xu
- 17.20 Clinical Practice Indicators for Queenslanders with NSCLC: How do we compare? – Tracey Guan
- 17.40 Treating people with cancer in Queensland and Victoria: National benchmarking starts here – Danica Cossio

Clinical trials

Plaza Level, P11

Chairs: Suzanne Elliott, Adam Stoneley

Recruitment and retention in Oncology Trials

- 16.30 Opening remarks – Suzanne Elliott
- 16.40 Recruitment/Retention cost considerations for Sponsor, Site and Patients – Stephanie Perkins
- 16.55 How do sites identify potential patients – Annabel Webber
- 17.05 Challenging eligibility criteria – Amber Ward
- 17.15 Issues with recruiting for Phase I Trials – Corrine Fiveash
- 17.25 Challenges of Participant reimbursements – Stephanie Airey
- 17.35 Dealing with the disgruntled Trial Participant – Amy Ives
- 17.45 Panel discussion – Rebecca Clarke, Rachel Wong

Conference Program

THURSDAY 28 NOVEMBER, 2024

DAY
1

Survivorship: New and Emerging Trends in Survivorship Care

Sky Level, S1

Chairs: Natalie Bradford, Rebecca Packer

- 16.30 A UNIQUE study to Understand the experiences and Identify the needs of Queenslanders affected by cancer – Belinda Goodwin
- 16.45 The effect of diet on cardiometabolic health outcomes of prostate cancer patients treated with androgen deprivation therapy: A systematic review – Hattie Wright
- 17.00 Life and health after childhood cancer: Real-world data for real-world problems – Jason Pole
- 17.15 The barriers, enablers and recommendations for improving access to financial aid when a child has cancer – Megumi Lim
- 17.30 Symptom assessment in cancer patients undergoing immunotherapy: Cultural considerations in Arabic-speaking adults with advanced disease – Fatimah Alquzi
- 17.45 Q/A and wrap up

Advocacy and consumer involvement in cancer care and research

Plaza Auditorium

Chairs: Alison Bolton, Anita McGrath, Michel IteI

Round Table Discussion

Gala Dinner, Brisbane Convention and Exhibition Centre (7.15pm 'til late)

Boulevard Room

Conference Program

FRIDAY 29 NOVEMBER, 2024

DAY
2

7am Registration Opens

Plenary Lectures (8.00 – 10.00)

Plaza Auditorium

Chairs: John Prins, Frank Gannon

- 08.00 Tumour environment and therapy in melanoma – Nikolas Haass
- 08.20 Multiomics Analysis of Paired Diagnosis and Relapse Diffuse Large B-Cell Lymphoma Biopsies Shows a Reduction in T-Cell Infiltration and Function at Relapse – Colm Keane
- 08.40 Tackling HPV malignancies with immunotherapy: cervical cancer – Kathryn Middleton
- 09.00 Liver transplant for colorectal liver metastases – Thomas O'Rourke
- 09.20 Unlocking early ovarian cancer detection: results from the circulating extracellular vesicles study – Carlos Salomon Gallo
- 09.40 Adolescent and Young Adults – Are You Aware? – Rick Walker

Refreshments (supported by Turner Freeman)

Parallel Workshops (10.30 – 12.00)

Pharmacy Research & Innovation Roundup

Plaza Level, P6

Chair: Dan McKavanagh

- 10.30 Proactive Risk Factor Screening to Enhance Chemotherapy-Induced Nausea and Vomiting Management: An Oncology Outpatient Pilot Study – Shweta Painumpra
- 10.47 From toxicity to recovery: A case report of a patient administered glucarpidase for methotrexate toxicity – Michael Whordley
- 11.04 Development and implementation of an Introductory Cancer Care Program: Impacts on knowledge, engagement and retention – Sarah Lumchee
- 11.21 Evaluation of Medication Management Education provided to patients in the Oncology Day Unit at Ipswich hospital – Guru Sule
- 11.38 Increasing safety for high dose methotrexate infusions – Ashlee Aitken
- 11.47 Pegasparginase exposure response analysis – Rachael Lawson
- 11.56 Concluding remarks

Upper GI and HBP malignancies

Plaza Level, P7

Chairs: Mark Nalder, Kate Roberts

- 10.30 CDCP1 and cholangiocarcinoma – Lash Wickramasuriya
- 10.42 Radiomics biomarkers are associated with survival in patients with Oesophageal Cancer – Lauren Aoude
- 10.54 Nutrition considerations during treatment for UGI cancer – Kelli Edmiston
- 11.06 Medical Oncology Updates in UGI/HPB – Yong Yeung
- 11.18 CLDN18 testing in gastric cancer – Jen Borowsky
- 11.30 Gastric Fill Protocol: Collaborative planning to reduce toxicity of neoadjuvant chemoradiotherapy for Oesophageal Cancer – Yang Hwang
- 11.42 Current recruiting GI trials in QLD – Kathy You

Conference Program

FRIDAY 29 NOVEMBER, 2024

DAY
2

Brain tumours		Plaza Level, P8
Chairs: Bryan Day, Mark Pinkham, Zarnie Lwin, Hamish Alexander		
10.30	Pre-op stereotactic radiosurgery for brain metastases: initial experience – Kimberley Budgen	
10.45	Trial in progress: immunotherapy for recurrent glioblastoma – David Walker	
11.00	Audit of molecular testing for glioblastoma at RBWH – Betty Zhang	
11.15	Suppressing recurrence in sonic hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179 – Michelle Li	
11.30	Enhanced telomerase targeting in glioblastoma via augmented 6-thio-2'-deoxyguanosine – Thomas Crawshaw	
11.45	Key role of Peace of Mind Foundation to provide support for people with brain tumours and their families – Fiona Hassmann	
3-D Cancer models		Plaza Level, P9
Chairs: Lisa Philp, Robert Ju, Nikolas Haass		
10.30	Assessing Immune Response in Melanoma by Generating Tumour-Specific CTLs and Co-Culturing with Spheroids – Yimeng Guan	
10.40	Mechanical manipulation of collagen and hyaluronic acid-based hydrogels for 3D cell studies – Marco Enriques Martinez	
10.50	Cytoskeletal-Golgi Crosstalk During Cellular Migration Through Confined Environments – Christanny Schmidt	
11.00	Vascularisation of human skin organoids for enhanced physiological relevance – Mitchell Mostina	
11.10	Novel 3D patient-derived organoids (PDOs) representing the tumour microenvironment (TME) for optimising precision therapy in metastatic endometrial cancer – Asmerom Sengal	
11.20	Application of in vitro 3D Models to Study the Effect of Hypofractionated Radiation Therapy for Patient-Derived Breast Cancer Cells – Son Phan	
11.30	Modelling KRAS mutant colorectal cancer in 3D – Bianca Nowlan	
11.40	Modelling the vasculature in disease with 3D microfluidic devices – Tish Essebier	
Gynae-oncology		Plaza Level, P10
Chairs: Carlos Solomon Gallo, Kathryn Middleton		
10.30	Targeting replication stress to improve immune recognition and reduce immunosuppressive in the tumour microenvironment – Brian Gabrielli	
10.40	Epigenetic regulation in ovarian cancer – Jason Lee	
10.50	Cytokines bound to ovarian cancer extracellular vesicles in ascites influence their uptake by receptor-expressing cells, impacting their function – Soumyalekshmi Nair	
11.00	Mesoporous Nanotechnology for Ovarian Cancer Detection – Mostafa Kamal Masud	
11.10	Developing new strategies to overcome immune suppression in cancer – Sarah Wilkey	
11:20	The Role of Visceral Adipose in Endometrial Cancer: Uncovering Mechanisms and Insights – Serena Gallozzi	
11.30	Safety, feasibility and effect of exercise for women receiving chemotherapy for recurrent ovarian cancer: results from the ECHO-R trial – Rosa Spence	
11.40	Endometrial cancer translational studies at QCGC research – Eva Baxter	
11.50	Summary: Carlos Salomon	
Thoracic Malignancies (supported by Boehringer-Ingelheim)		Plaza Level, P11
Chairs: Tim Edwards, Gishan Ratnayake		
10.30	Recent updates on thoracic oncology – Zulfiqar Otti	
10.45	Real World Data for Trial validation and biomarker studies – William Mullally	
11.00	Rationale for PRIME lung study – Margot Lehman	
11.10	Management of oligometastatic disease – Gishan Ratnayake	
11.20	Surgery and opportunities for translational research – Morgan Windsor	
11.30	Research snapshots <ul style="list-style-type: none"> • Targeting a novel DNA repair protein in NSCLC – Amila Suraweera • Unique strategies to reverse EGFR Tyrosine Kinase Inhibitor resistance – Mark Adams • KRAS in NSCLC – Lauren Ashwood 	
11.45	Discussion	
Youth Cancer workshop		Plaza Auditorium
Chairs: Rick Walker, Katie Lindeberg		
10.30	Introduction to Queensland Youth Cancer Service – Katie Lindeberg	
10.45	Brain Tumours in the AYA population – Rick Walker	
11.05	Survivorship in AYA Cancer – Sandra Gleaves	
11.20	Loss in the AYA Space – Kylie McPaul & Ainslie Plumb	
11.50	Concluding Statements – Katie Lindeberg	
Lunch (12.00)		

Conference Program

FRIDAY 29 NOVEMBER, 2024

DAY
2

Plenary Lectures (12.30 – 14.00)

Plaza Auditorium

Chairs: Helen Benham, Bena Brown

- 12.30 Multi-Omics: The key to precision oncology – Arutha Kulasinghe
- 12.50 De-escalation of immunotherapy: a paradigm shift in patient care – Rahul Ladwa
- 13.10 Mesothelioma: A model for Precision Medicine in Oncology – Dean Fennell
- 13.30 Impact of exercise on cancer survival – Robert Newton
- 13.50 Achieving Cancer Care Equity for Aboriginal and Torres Strait Islander Queenslanders – Gail Garvey

Refreshments (14.10)

Parallel Workshops (14.30 – 16.00)

Haematology

Plaza Level, P6

Chairs: Colm Keane, Stephen Boyle

- 14.30 Multiomics analysis of immune checkpoint response in follicular lymphoma – Rakin Chowdhury
- 14.47 Practices and outcomes during a watch and wait approach for follicular lymphoma: a study from the Australasian Lymphoma Alliance – Luani Barge
- 15.04 Managing haematological malignancies in pregnancy – Caroline Wilson
- 15.21 Cellular Therapy in Cancer Care – Experiences from MSKCC – Karthik Nath
- 15.38 PICCing the Best PICC: lessons and insights from a multicentre trial and qualitative study – Deanne August

Palliative Care

Plaza Level, P7

Chairs: Ben Gunawan, Philip Goode

- 14.30 Teletrials in Palliative Care – Claire Stokes
- 14.45 Using the Surprise Question in Routine Assessment to Support Best Practice Advance Care Planning and End of Life Care – Arvind Gunasekaran
- 15.00 "MINI steps forwards": Update on a clinical trial of medicinal cannabis in children with advanced cancer – Anthony Herbert
- 15.15 Cancer, Cannabis & Caregiving: Preliminary Findings from Qualitative Analysis of Carer's Perspectives – Maddison Cuerton
- 15.30 Managing treatment-refractory diarrhoea in palliative care – Trish Kahawita
- 15.45 Discussion and closing remarks

GI malignancies

Plaza Level, P8

Chairs: Vicki Whitehall, Mark Bettington, Matt Burge

- 14.30 The Impact of Clinical Mutation Testing on Management of Gastrointestinal Cancer – Jennifer Borowsky
- 14.45 Development of Patient Derived Organoid Based Predictive Drug Testing for Rectal Cancer – Krystal Lianos
- 15.00 Latest Advances in Immunotherapy for Colorectal and Anal Cancer: Game Changing Updates from ASCO and ESMO – Matthew Burge
- 15.15 Preclinical Data to Clinical Trial Development: Showcasing an Exciting Clinical Research Collaboration – Vicki Whitehall
- 15.30 Liver Transplant for Metastatic Colorectal Cancer – Pramudith Sirimanna
- 15.45 Discussion

Multiomics

Plaza Level, P9

Chair: Arutha Kulasinghe

- 14.30 SpaMTP: integrating spatial metabolomics with spatial transcriptomics – Andrew Causer
- 14.45 Immune checkpoint expression in whole slide tissues – Courtney Waller
- 15.00 Spatial metabolic profiling in head and neck cancer – Naomi Berrell
- 15.15 Spatial interaction mapping of PD-1/PD-L1 – Vahid Yaghoubi Naei
- 15.30 Developing an Integrated spatial proteomic analysis pipeline – Rafael Tubelleza
- 15.45 Mapping and comparing spatial community features across cancer patients – Feng Zhang

Melanoma

Plaza Level, P10

Chairs: Hannah Neuendorf, Wen Xu, Nikolas Haass

- 14.30 Autophagy in MITF-driven phenotypic heterogeneity of melanoma – Gisella Edny
- 14.40 Exploring the Genetics of Melanoma Risk Factors – Shanika Jayasinghe
- 14.50 TILS and other TOOLS of the trade – Robert Mason
- 15.00 Peptide scaffolds as potential tools for Melanoma therapy – Henry Lamb
- 15.10 Investigating the tumour environment of melanoma brain metastases – Clémence Belle
- 15.20 ROCK-inhibition sensitises dormant melanoma cells to BRAF/MEK inhibitors – Kota Tachibana
- 15.30 Neoadjuvant immunotherapy in resectable stage III melanoma – Marcin Dzenis
- 15.50 Targeting the BRN2 Transcription Factor in Melanoma – Hannah Neuendorf

Conference Program

FRIDAY 29 NOVEMBER, 2024

DAY
2

Breast cancer (supported by Daiichi-Sankyo) Plaza Level, P11

Chairs: Pete Simpson, Rik Thompson, Jodi Saunas

- 14.30 Identifying the risk of breast cancer recurrence from the Queensland Oncology Repository – Meghan Stephensen
- 14.48 The differentiation detective: tracking epigenomic regulation to explore the BRCA1-TNBC connection – Anna Alvsaker
- 15.07 Using targeted alpha particle therapy for in-situ vaccination – Jodi Saunas
- 15.25 Exploiting immunogenic cell death and proteasome inhibition to improve cancer immunotherapy – Davide Moi
- 15.45 The immunoregulatory effect of radiotherapy and anti-VISTA in a preclinical model of TNBC – Chelsea Kralik

Head and neck cancer Sky Level, S1

Chairs: Sarju Vasani, Margaret McGrath

- 14.30 Investigating the impact of skull base surgery on nutrition and swallowing outcomes – Joanne Hiatt
- 14.35 Final analysis of a prospective study evaluating sexual health, facial appearance, and appearance distress in patients with human papillomavirus-associated oropharyngeal cancer patients treated with chemoradiation – Lachlan McDowell
- 14.42 Toxicities and functional impacts of immune check-point inhibitor therapy for head and neck cancer: A scoping review – Nicole O'Donnell
- 14.47 Lymphatic imaging with ICG lymphography for head and neck lymphoedema – Megan Trevethan
- 14.52 Discussion – Treatment toxicity. Can we de-escalate and how?
- 15.02 A tumour-informed ctDNA detection workflow in head and neck cancer patients – Xiaomin (Celeste) Huang
- 15.07 Saliva and Plasma-Derived Small Extracellular Vesicles: Promising Prognostic Biomarkers for Head and Neck Cancers – Abolfazi Jangholi
- 15.12 Discussion Biomarkers – How do we incorporate these in clinical trials?
- 15.22 Spatial Multi-Omics Analysis of HPV-Positive Head and Neck Cancer: Tumour Oncogenesis and Discovery of Targeted Therapies – Lisa Xuehan Lu
- 15.27 Deep Spatial Profiling of the Head and Neck Tumour Microenvironment for Predictors of Response and Resistance to Immunotherapy – James Monkman
- 15.32 Applications of proteomics to cHNSCC with perineural spread – Jonathan P Helena
- 15.37 Discussion – is more data necessarily better?

Refreshments (14.00)

Plenary session (16.15 – 17.15) Plaza Auditorium

Chairs: Kenneth O'Byrne, Arutha Kulasinghe



The impact of AI on cancer research

- 16.15 Foundation Digital pathology models: From computational pathology to spatial biology – Carlo Bifulco
- 16.40 MultiOmics and mesothelioma – Dean Fennell
- 17.00 Q&A


Wine and cheese (17.15 – 18.15)




Venue Floor Plans



Plaza Level



Boulevard Level



Sponsor Floor Plan

BMS	1
MSD	2
AstraZeneca	3
Janssen	4
Roche	5
Bayer	6
Gilead	7
Eisai	8
Boehringer-Ingelheim	9
Ipsen	10
GSK	11
Sun Pharma	12
Merck	13
Astellas	14
Pfizer	15
Lilly-Oncology	16
Medison	17
Novartis	18
Lung Foundation Australia	19
ADSS	20
Turner Freeman	21
I-Inscribe	T1
Pierre-Fabre	T2
Ariceum	T3
Queensland Youth Cancer Services	T4

